Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580606 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00580606 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 40 participants.
The verdict
NCT00580606, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut allergies.
Interventions
- DRUG Glycerinated peanut allergenic extract
- DRUG Placebo for peanut extract (glycerin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580606
The ClinicalTrials.gov registry entry for NCT00580606 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glycerinated peanut allergenic extract is the first listed.
NCT00580606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00580606 about?
NCT00580606 is a clinical study titled "A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial". The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut allergies.
What is the current status of trial NCT00580606?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2007-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00580606?
The interventions under investigation include: Glycerinated peanut allergenic extract (DRUG), Placebo for peanut extract (glycerin) (DRUG).
Who is sponsoring clinical trial NCT00580606?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.